CE Antimicrobial Stewardship

Resistance in gram-positive organisms

• Identify the major mechanisms of antibiotic resistance in gram-positive bacteria including mecA-mediated methicillin resistance, vanA and vanB vancomycin resistance, and macrolide resistance mechanisms.
• Explain the clinical significance of MRSA versus MSSA infections and the treatment implications for empiric therapy selection in skin and soft tissue infections and bacteremia.
• Describe vancomycin-resistant enterococcal infections including risk factors, available treatment options such as daptomycin and linezolid, and infection control measures to prevent transmission.
• Analyze the emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus and evaluate the therapeutic options and infection control implications.

Resistance in gram-negative organisms

• Identify the major beta-lactamase classifications including AmpC, ESBLs, and carbapenemases (KPC, NDM, OXA-48) and the antibiotics they hydrolyze.
• Explain the treatment approach for ESBL-producing Enterobacterales including the role of carbapenems, beta-lactam/beta-lactamase inhibitor combinations, and cefiderocol.
• Analyze the global epidemiology of carbapenem-resistant organisms and evaluate the clinical and public health implications of pan-drug resistant gram-negative infections.
• Evaluate the role of rapid diagnostic tests including PCR panels and MALDI-TOF in identifying resistance mechanisms earlier and their impact on antimicrobial stewardship outcomes.

Empiric therapy selection

• Identify the principles of empiric antimicrobial selection including likely pathogens by infection site, local antibiogram data, patient risk factors, and severity of illness assessment.
• Explain the role of facility-specific antibiograms in guiding empiric antibiotic selection and the methodology for antibiogram construction and interpretation.
• Describe the concept of syndrome-specific treatment guidelines for common infections including community-acquired pneumonia, urinary tract infections, and intra-abdominal infections.
• Analyze empiric antibiotic choices for a septic patient considering local resistance patterns, recent antibiotic exposure, healthcare-associated risk factors, and infection source uncertainty.

Culture-directed therapy

• Explain the interpretation of culture and sensitivity reports including MIC values, breakpoint classifications, and the distinction between susceptible, intermediate, and resistant categories.
• Analyze culture results to determine optimal targeted therapy considering spectrum narrowing, bioavailability, tissue penetration, and patient-specific factors.
• Evaluate situations where empiric therapy should be continued despite negative cultures including culture-negative endocarditis, partially treated infections, and biofilm-associated infections.
• Design a process for timely culture review and antimicrobial adjustment that includes laboratory notification systems, pharmacist review, and prescriber communication workflows.

De-escalation principles

• Identify the criteria for safe antimicrobial de-escalation including clinical improvement, culture susceptibility data, biomarker trends, and infection source control.
• Explain IV-to-oral antimicrobial conversion criteria including hemodynamic stability, functioning GI tract, oral bioavailability equivalence, and agents suitable for oral step-down.
• Describe the evidence supporting shorter antibiotic durations for common infections including community-acquired pneumonia, urinary tract infections, skin infections, and intra-abdominal infections.

Implementation and monitoring

• Analyze clinical scenarios to determine appropriate de-escalation timing and strategy including narrowing spectrum, shortening duration, and converting from IV to oral administration.
• Evaluate the role of procalcitonin and other biomarkers in guiding antibiotic duration decisions and the evidence supporting biomarker-guided antibiotic stewardship.
• Identify barriers to antimicrobial de-escalation including prescriber discomfort, diagnostic uncertainty, patient expectations, and lack of oral alternatives.
• Design a de-escalation decision support tool that integrates culture results, clinical improvement criteria, biomarker data, and oral switch eligibility into a standardized assessment.

CDI risk factors and prevention

• Identify the modifiable risk factors for Clostridioides difficile infection including broad-spectrum antibiotic use, fluoroquinolone exposure, proton pump inhibitor use, and prolonged hospitalization.
• Explain the antimicrobial stewardship interventions that reduce CDI rates including fluoroquinolone restriction, cephalosporin minimization, and targeted antibiotic use based on institutional data.
• Describe the current treatment approach for initial and recurrent CDI including fidaxomicin, oral vancomycin, bezlotoxumab, and fecal microbiota transplantation indications.

CDI stewardship integration

• Analyze the relationship between specific antimicrobial prescribing patterns and CDI incidence to identify high-risk prescribing practices amenable to stewardship intervention.
• Evaluate diagnostic stewardship for CDI testing including appropriate test selection, avoidance of test-of-cure, and the clinical impact of NAAT versus toxin EIA testing strategies.
• Identify infection prevention measures for CDI including contact precautions, hand hygiene with soap and water, environmental cleaning with sporicidal agents, and patient isolation criteria.
• Design a CDI prevention bundle that integrates antimicrobial stewardship, diagnostic stewardship, infection prevention measures, and outcome surveillance into a coordinated program.

Antifungal therapy optimization

• Identify the major antifungal drug classes including azoles, echinocandins, polyenes, and flucytosine and their spectrum of activity against Candida, Aspergillus, and other fungal pathogens.
• Explain the role of diagnostic biomarkers including beta-D-glucan, galactomannan, and T2Candida in guiding antifungal therapy initiation and de-escalation decisions.
• Analyze the appropriate empiric antifungal selection for candidemia based on patient risk factors, prior azole exposure, local resistance patterns, and severity of illness.

Antifungal program development

• Evaluate antifungal therapeutic drug monitoring requirements for voriconazole and posaconazole including target trough levels, timing, and dosage adjustment strategies.
• Identify the emerging resistance patterns in Candida species including Candida auris multidrug resistance and the infection control implications of resistant fungal pathogens.
• Design an antifungal stewardship component for an ASP program including preauthorization criteria, diagnostic-driven therapy protocols, de-escalation triggers, and cost-impact analysis.

PK/PD principles

• Identify the three primary PK/PD indices for antimicrobial efficacy including time above MIC for beta-lactams, AUC/MIC for vancomycin and fluoroquinolones, and Cmax/MIC for aminoglycosides.
• Explain the pharmacokinetic rationale for extended and continuous infusion of beta-lactam antibiotics and the clinical evidence supporting improved outcomes over intermittent dosing.
• Describe AUC-guided vancomycin dosing as recommended by the 2020 consensus guidelines including target AUC/MIC ratios, calculation methods, and advantages over trough-only monitoring.

Clinical PK/PD application

• Analyze dosing optimization scenarios for critically ill patients with altered pharmacokinetics including augmented renal clearance, third-spacing, and obesity-related volume changes.
• Evaluate aminoglycoside dosing strategies including extended-interval dosing using the Hartford nomogram and traditional dosing for synergy in endocarditis.
• Identify the dosing considerations for antimicrobials in renal replacement therapy including hemodialysis, CRRT, and peritoneal dialysis and the factors affecting drug removal.
• Design a PK/PD-optimized antimicrobial dosing protocol for an ICU setting that addresses extended infusions, AUC-guided vancomycin, renal-adjusted dosing, and therapeutic drug monitoring.

Core elements and strategies

• Identify the CDC Core Elements of Hospital Antibiotic Stewardship Programs including leadership commitment, accountability, drug expertise, action, tracking, reporting, and education.
• Explain the two primary ASP strategies of prospective audit and feedback versus preauthorization and the evidence comparing their effectiveness and prescriber acceptance.
• Describe the antibiogram development process including data collection standards, reporting thresholds, combination antibiogram construction, and annual update and dissemination procedures.

Program outcomes and sustainability

• Analyze the key performance indicators for antimicrobial stewardship programs including days of therapy per 1000 patient-days, defined daily doses, resistance trends, and CDI rates.
• Evaluate the role of clinical pharmacists and infectious disease physicians as ASP team leaders and the evidence supporting multidisciplinary team composition for program success.
• Identify strategies for extending antimicrobial stewardship to outpatient settings including urgent care, long-term care facilities, and ambulatory clinics.
• Design a comprehensive antimicrobial stewardship program proposal for a community hospital including team structure, intervention strategies, technology requirements, outcome metrics, and budget justification.

Diagnostic stewardship

• Identify the principles of diagnostic stewardship including appropriate culture collection, avoidance of unnecessary testing, and the impact of contaminated cultures on antimicrobial prescribing.
• Explain the clinical impact of rapid diagnostic technologies including blood culture identification panels, antibiotic resistance gene detection, and MALDI-TOF mass spectrometry on time to optimal therapy.
• Analyze the phenomenon of asymptomatic bacteriuria and the evidence against treatment in most populations to reduce unnecessary antibiotic use.
• Design a diagnostic stewardship initiative that addresses blood culture contamination rates, urine culture ordering practices, and integration of rapid diagnostics with ASP interventions.

Special populations

• Describe antimicrobial dosing considerations for obese patients including weight-based dosing thresholds, volume of distribution changes, and renal clearance adjustments.
• Explain antimicrobial stewardship challenges in immunocompromised patients including the tension between broad empiric coverage and stewardship principles in neutropenic fever.
• Evaluate antimicrobial prescribing in long-term care facilities including common inappropriate prescribing patterns, diagnostic challenges, and stewardship interventions effective in this setting.
• Analyze the One Health perspective on antimicrobial resistance including the connections between human antibiotic use, agricultural practices, environmental reservoirs, and resistance gene transfer.

Identify the prevalence of reported penicillin allergies and the evidence that most patients labeled penicillin-allergic can safely receive beta-lactam antibiotics after proper evaluation.

Explain the clinical approach to penicillin allergy evaluation including risk stratification, skin testing, graded challenge protocols, and direct oral challenge criteria.

Analyze the impact of penicillin allergy labels on antimicrobial prescribing including increased use of broad-spectrum alternatives, higher costs, and adverse outcome associations.

Design a pharmacist-led penicillin allergy delabeling program including patient identification, risk stratification algorithm, testing protocols, and electronic health record documentation updates.